Premium
Adsorption Column for Myasthenia Gravis Treatment: MedisorbaMG‐50
Author(s) -
Nakaji Shuhei,
Hayashi Nobuyuki
Publication year - 2003
Publication title -
therapeutic apheresis and dialysis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.415
H-Index - 53
eISSN - 1744-9987
pISSN - 1744-9979
DOI - 10.1046/j.1526-0968.2003.00008.x
Subject(s) - myasthenia gravis , acetylcholine receptor , medicine , peptide , antibody , acetylcholine , in vitro , ligand (biochemistry) , chromatography , titer , sepharose , receptor , biochemistry , pharmacology , immunology , chemistry , enzyme
Adsorption column Medisorba MG‐50 (Kuraray MedicalInc.) for the treatment of myasthenia gravis (MG) is introduced.The adsorbent in this column is composed of cellulose beads as carriermaterial and covalent‐bound synthetic peptide as a ligand that hasa specific affinity to the pathogenic anti‐acetylcholine receptorantibody of MG. The amino acid sequence of the peptide is modifiedfrom the segment of alpha 183–200 of the torpedo acetylcholine receptor(AChR) protein, and the segment is the acetylcholine binding siteon AChR and the target site of anti‐AChR antibody. The adsorbentshowed specific adsorption characteristics to the anti‐ACHR antibody(blocking antibody) in vitro. Clinically, MG‐50 is used in plasma‐perfusiontherapy, and it is recognized that MG‐50 specificallyreduces blocking antibody titer and improves MG symptoms. MG‐50is approved in Japan.